Pfizer dropped the ball on Celldex. They would be high tailing it to the goal line with Celldex's pipeline of immunotherapies right now, but instead ar eon the outside looking in at the best fully-independent immunocology company. Too bad, so sad.
Pfzer's price went up on #$%$ news. I guess the thinking is that they have a portfolio of drugs. However, even though its small size, Celldex's portfolio of immunotgerapeutics is much more robust than pfizer's.